Curriculum Vitaes
Profile Information
- Affiliation
- Professor, Faculty of Medical Sciences, Fujita Health University理事長, 医薬品適正使用推進機構, NPO
- Degree
- Ph.D.
- J-GLOBAL ID
- 201101030936121945
- researchmap Member ID
- B000004803
- External link
藤田医科大学大学院医療科学研究科 客員教授
学歴
1968年3月岐阜薬科大学製薬学科卒業
1973年3月大阪大学大学院薬学研究科博士課程単位取得後中退
1977年12月東北大学にて博士号修得(薬学)
職歴
1973年 4月名城大学薬学部 助手
1978年10月~1981年5月米国ミシシッピー州立大学メディカルセンター 客員助教授
1982年 4月名城大学薬学部 講師
1984年 4月名城大学薬学部 助教授
1990年 1月名古屋大学大学院医学系研究科臨床情報学講座医療薬学分野・医学部附属病院薬剤部 教授・部長(併任)
2006年 1月特定非営利活動法人医薬品適正使用推進機構理事長
2007年 3月名古屋大学を定年退職
2007年 4月より名城大学大学院薬学研究科 薬品作用学研究室 教授
2012年 3月名城大学を定年退職
2012年 4月より名城大学薬学部寄附講座 地域医療薬局学講座特任教授
2015年 3月より名城大学薬学部 特任教授
2015年12月より藤田医科大学大学院保健学研究科(現 医療科学研究科) 客員教授
現在の主な研究分野:神経精神薬理学:精神疾患動物モデルの作成と新薬開発への応用、薬物依存、医薬品の適正使用についての研究
Research Interests
31Research Areas
5Research History
10-
Apr, 2015 - Mar, 2016
-
Apr, 2011 - Mar, 2015
-
2007 - 2011
-
1990 - 2007
Education
3Committee Memberships
4-
2004 - Present
-
2001 - Present
-
1992 - Present
-
2008 - 2010
Awards
9-
2008
-
2007
-
2001
Papers
794-
Behavioural Brain Research, 496 115832-115832, Jan, 2026
-
British Journal of Pharmacology, Dec 21, 2025Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress (CUMS) and were evaluated by behavioural, neurochemical and metabolic analysis. Key Results Health check‐up data showed increased sucrose intake in MDD patients. When mice received sucrose under CUMS, hyperactivity and aggression were attenuated, although social deficits or behavioural despair induced by CUMS persisted, and recognition memory was impaired. The behavioural changes were associated with dysfunction of the locus coeruleus‐prefrontal cortex circuit, caused by impaired noradrenaline release due to presynaptic α 2 ‐adrenoceptor upregulation, and postsynaptic α 1 ‐adrenoceptor and β 1 ‐adrenoceptor downregulation. α 2 ‐Adrenoceptor antagonism by atipamezole rescued behavioural changes induced by sucrose intake under CUMS, whereas α 2 ‐adrenoceptor agonism by guanfacine in CUMS mice mimicked these behavioural changes. Among the antidepressants, mirtazapine effectively increased noradrenaline release and rescued behavioural changes induced by sucrose intake under CUMS. Sucrose intake under CUMS induced peripheral hyperglycaemia and dysregulation of central glucose metabolism. Glucose transporter inhibition by phloretin rescued behavioural changes induced by sucrose intake under CUMS. Intracerebroventricular and systemic streptozotocin administration reproduced these behavioural changes and α 2 ‐adrenoceptor upregulation. Conclusions and Implications Our findings suggest that the observed behavioural changes are associated with dysfunction of the noradrenergic α 2 ‐adrenoceptor system induced by impaired glucose metabolism. These insights targeting the noradrenergic‐metabolic axis might be a new strategy for sugar‐induced depression subtypes.
-
Journal of Neurochemistry, 169(11), Nov 20, 2025ABSTRACT Psychiatric disorders such as major depressive disorder are closely linked to the intestinal environment, suggesting intestinal health may contribute to their prevention. Prebiotics, which enhance intestinal health, are promising candidates for preventing psychiatric disorders. 1‐Kestose (kestose), a type of prebiotics, has shown potential, but its effects on psychiatric disorders remain unclear. In this study, we investigated whether kestose prevents abnormal behaviors induced by social isolation (SI) stress and which underlies mechanisms of preventive effects. C57BL/6J male mice (3 weeks old) were divided into two groups: individually housed (SI) group and housed five mice per cage (GH) group. Each group received either a normal diet or a kestose diet (5% kestose) for 5 weeks daily until the end of the behavioral testing. Kestose prevented the SI‐induced abnormal behaviors including reduced sociality, impaired spatial recognition, and heightened anxiety, which were associated with suppressed microglial activation in the hippocampus. Kestose altered the diversity of gut microbiota and increased the abundance of Bacteroides sartorii . Furthermore, short‐chain fatty acids (SCFAs) such as butyric acid, acetic acid, and propionic acid, produced by intestinal microbiota, were increased after kestose supplementation. Positive correlations were observed between B. sartorii abundance and SCFA levels, suggesting that B. sartorii contributes to SCFA production. Notably, both B. sartorii and SCFAs were strongly associated with the abnormal behaviors by SI. These findings suggest that kestose prevents SI‐induced abnormal behaviors by modulating gut microbiota, particularly B. sartorii , through an increase of SCFA production. Taken together, kestose could be used as a promising prebiotic intervention for psychiatric disorders. image
-
European Journal of Pharmacology, 178407-178407, Nov, 2025
-
Pharmacological Research, 221 107986-107986, Nov, 2025
Misc.
950-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 272P-272P, 2005
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 97 129P-129P, 2005
-
Molecular mechanisms of cognitive deficits associated with N-methyl-D-aspartate receptor dysfunctionJOURNAL OF PHARMACOLOGICAL SCIENCES, 97 53P-53P, 2005
-
依存性薬物および未規制薬物による神経毒性と精神病の発現機序 平成16年度 総括研究報告書, 13-20, 2005
-
J. Pharmacol. Sci., 97 157-161, 2005
-
J. Pharmacol. Sci., 97 1-5, 2005
-
日本薬理学雑誌 : FOLIA PHARMACOLOGICA JAPONICA, 124 119P-120P, Nov 1, 2004
-
Journal of toxicological sciences, 29(4) 282-282, Oct 29, 2004
-
Journal of toxicological sciences, 29(4) 308-308, Oct 29, 2004
-
24(5) 314-314, Oct 25, 2004
-
行動計量学, 31(2) 139-139, Sep 10, 2004
-
行動計量学, 31(2) 139-139, Sep 10, 2004
-
日本医療薬学会年会講演要旨集, 14 269-269, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 276-276, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 279-279, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 298-298, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 299-299, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 365-365, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 374-374, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 375-375, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 379-379, Sep 1, 2004
-
日本医療薬学会年会講演要旨集, 14 377-377, Sep 1, 2004
-
神経化学, 43(2-3) 510-510, Aug, 2004
-
日本薬理学雑誌, 124(2) 17P-17P, Aug, 2004
-
Schizophrenia Frontier, 5(3) 148-153, Aug, 2004統合失調症の主要な仮説に基づき,作製された以下の薬理学的病態動物モデルについて概説した.1)ドパミン過剰仮説に基づいて覚醒剤を投与された動物モデル,2)セロトニン異常仮説に基づいて幻覚剤を投与された動物モデル,3)グルタミン酸低下仮説に基づいてphencyclidineを投与された動物モデル,4)神経発達障害仮説に基づいて新生仔期に薬物を投与することによって脳の構造・発達異常を誘発させた動物モデル
-
神経化学, 43(2-3) 510-510, Aug, 2004
-
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 30(5) 330-334, May 10, 2004We report on the cutaneous adverse reactions of gefitinib (Iressa), an orally active, selective epidermal growth factor (EGF) receptor tyrosine kinase inhibitor that blocks signal transduction pathways, in a 19-year-old woman with recurrent malignant glioma. When treated daily with 250 mg gefitinib (p.o), the patient developed severe itching (Grade 2) and seborrheia (Grade 2) in the scalp, and acneiform eruption on the face (Grade 1) and upper limbs (Grade 1). The application of fluocinonide lotion to her scalp did not improve the symptoms, but the antihistaminic ebastine was effective. These cutaneous adverse reactions result from of gefitinib's direct interference with EGF receptor signaling in the skin and further studies should be conducted to elucidate the mechanisms by which they occur.
-
Molecular Pharmacology, 65(5) 1293-1301, May, 2004 Peer-reviewed
-
J Neurosci, 24 2212-2225, Apr, 2004 Peer-reviewed
-
日本薬理学雑誌 : FOLIA PHARMACOLOGICA JAPONICA, 123(3) 219-222, Mar 1, 2004
-
精神薬療研究年報, (36) 127-133, Mar, 2004phencyclidine(PCP)を連続投与したマウスが,統合失調症症状の1つである認知障害を発現するかどうかを行動解析し,認知障害の発現機序について併せて検討した.PCP動物モデルは,統合失調症様の認知障害を示す動物モデルとして有用で,認知障害の発現には,N-メチル-D-アスパラギン酸受容体を介する細胞内シグナル伝達系の低下が関与しているものと示唆された
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 227P-227P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 175P-175P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 175P-175P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 89P-89P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 15P-15P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 225P-225P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 238P-238P, 2004
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 94 18P-18P, 2004
Books and Other Publications
14Presentations
13-
日本医療薬学会年会講演要旨集, Oct 25, 2010
Research Projects
40-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2026
-
科学研究費助成事業 基盤研究(B), 日本学術振興会, Apr, 2023 - Mar, 2026
-
科学研究費助成事業 基盤研究(C), 日本学術振興会, Apr, 2020 - Mar, 2023
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2022
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2017 - Mar, 2022




